PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
about
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Checkpoint inhibitors in hematological malignanciesPD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.Diagnosis and treatment of CD20 negative B cell lymphomas.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.The diagnosis and management of NK/T-cell lymphomas.Epstein-Barr Virus LMP1 Mediated Oncogenicity.The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.Clinical Development of PD-1 Blockade in Hematologic Malignancies.Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.Evaluation of latent membrane protein 1 and microRNA-155 for the prognostic prediction of diffuse large B cell lymphoma.Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.Current Immunotherapeutic Approaches in T Cell Non-Hodgkin LymphomasNew developments in immunotherapy for lymphomaThe prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis
P2860
Q33638083-5DE1E430-7984-4400-87C3-934F80379E16Q33651495-B42CA613-2B64-4375-95C7-6F8C980DDCA5Q33839204-196932DA-BDF5-4777-B9D1-EA23337B9A6BQ38737954-E369D2A3-80FC-4A4E-91CC-475D9CF94171Q39132786-0E988B9B-C460-45F0-A8C7-636CD67D450CQ39237785-F68F3DA1-EBDE-49AD-A72D-F8C576F64F23Q39243241-619A349A-3E46-449D-9C1B-C61227B658A0Q40073030-314A1AC8-C202-469B-8FDB-7BAAB364B15CQ45325729-58694C2D-0CFD-4055-9BD0-F8D9D15BAC7AQ48517891-31B2FC11-03B2-4BAC-88EB-01874D496DCEQ48526801-0176899B-54F2-49FF-8861-66CDAC9F94B5Q49309172-92238093-92E8-4E4E-8B63-04AA71154F95Q54213148-1A5DB39B-C266-4687-A25B-4749C2FC562BQ54962558-BD73690D-080F-4744-BE29-7042CB5E9A11Q55094448-F0EA2B63-29DD-4DA4-9A34-4DA362777E9AQ58723337-BECF5B4C-7FB7-499E-B88E-821A3FCF834BQ58804962-D7971D38-B88A-476D-88C4-80447B8581F9Q58804963-416D6186-CEF7-4D49-9FA1-AE85DE8B91A3
P2860
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PD-L1 is upregulated by EBV-dr ...... atural killer/T-cell lymphoma.
@en
PD-L1 is upregulated by EBV-dr ...... atural killer/T-cell lymphoma.
@nl
type
label
PD-L1 is upregulated by EBV-dr ...... atural killer/T-cell lymphoma.
@en
PD-L1 is upregulated by EBV-dr ...... atural killer/T-cell lymphoma.
@nl
prefLabel
PD-L1 is upregulated by EBV-dr ...... atural killer/T-cell lymphoma.
@en
PD-L1 is upregulated by EBV-dr ...... atural killer/T-cell lymphoma.
@nl
P2093
P2860
P1476
PD-L1 is upregulated by EBV-dr ...... atural killer/T-cell lymphoma.
@en
P2093
Hui-Qiang Huang
Jing-Hua Wang
Liang Wang
Wen-Jian Liu
Wen-Qi Jiang
Wen-Wen Zhang
Yu-Jing Zhang
Zhong-Jun Xia
P2860
P2888
P356
10.1186/S13045-016-0341-7
P577
2016-10-13T00:00:00Z
P6179
1009567394